Phibro Animal Health's acquisition of Zoetis' medicated feed additive business has driven significant momentum and improved financial performance. Organic growth and margin expansion is seen across all segments, not just from the Zoetis deal, signaling a real operational turnaround. Despite a 50% share price rally, the stock remains attractively valued at a low double-digit earnings multiple, with manageable leverage.
Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Ms. Kristin C. Peck CEO | XHAN Exchange | US98978V1035 ISIN |
US Country | 13,800 Employees | 18 Jul 2025 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |